造血干细胞基因治疗脑型肾上腺脑白质营养不良
这项单组开放标签2-3期研究纳入17例早期脑型肾上腺脑白质营养不良男童,输注Lenti-D慢病毒载体转导的自体CD34+细胞。中期分析中位随访29.4个月,15例(88%)存活且无主要功能残疾,无治疗相关死亡或移植物抗宿主病。早期结果提示该疗法可能成为早期患者异基因造血干细胞移植的安全有效替代方案。
要点
- 17例早期脑型肾上腺脑白质营养不良男童接受Lenti-D基因治疗,中位随访29.4个月。
- 15/17例(88%)存活且无主要功能残疾,临床症轻微。
- 无治疗相关死亡或移植物抗宿主病报告。
核心结论
- 早期结果提示Lenti-D基因治疗可能成为早期脑型肾上腺脑白质营养不良男童异基因造血干细胞移植的安全有效替代方案。
- 需要进一步随访以全面评估缓解持续时间和长期安全性。
研究设计与样本
- 单组、开放标签、2-3期安全性和有效性研究。
- 纳入要求为早期疾病且筛查时磁共振成像(MRI)显示钆增强的脑型肾上腺脑白质营养不良男童。
- 研究干预为输注经elivaldogene tavalentivec(Lenti-D)慢病毒载体转导的自体CD34+细胞。
- 中期分析评估移植物抗宿主病、死亡、主要功能残疾的发生情况,以及神经功能和MRI病灶范围的变化。
- 主要终点为输注后24个月时存活且无主要功能残疾。
主要发现
- 共17例男童接受了Lenti-D基因治疗。
- 中期分析时中位随访29.4个月(范围21.6至42.0)。
- 所有患者植入后均有基因标记细胞,未发现已知癌基因附近优先整合或克隆性生长的证据。
- 所有患者均可检测到ALD蛋白。
- 未报告治疗相关死亡或移植物抗宿主病;17例中15例(88%)存活且无主要功能残疾,临床症轻微。
关键数值与推荐
- 主要终点:输注后24个月存活且无主要功能残疾,17例中15例(88%)达到。
- 中位随访29.4个月(范围21.6至42.0)。
- 所有患者植入后均有基因标记细胞,所有患者均可检测到ALD蛋白。
- 未报告治疗相关死亡或移植物抗宿主病。
临床怎么用
- 早期结果提示Lenti-D基因治疗可能成为早期脑型肾上腺脑白质营养不良男童异基因造血干细胞移植的安全有效替代方案。
- 需要进一步随访以全面评估缓解持续时间和长期安全性。
局限性
- 需要进一步随访以全面评估缓解持续时间和长期安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In X-linked adrenoleukodystrophy, mutations in ABCD1 lead to loss of function of the ALD protein. Cerebral adrenoleukodystrophy is characterized by demyelination and neurodegeneration. Disease progression, which leads to loss of neurologic function and death, can be halted only with allogeneic hematopoietic stem-cell transplantation. METHODS: We enrolled boys with cerebral adrenoleukodystrophy in a single-group, open-label, phase 2-3 safety and efficacy study. Patients were required to have early-stage disease and gadolinium enhancement on magnetic resonance imaging (MRI) at screening. The investigational therapy involved infusion of autologous CD34+ cells transduced with the elivaldogene tavalentivec (Lenti-D) lentiviral vector. In this interim analysis, patients were assessed for the occurrence of graft-versus-host disease, death, and major functional disabilities, as well as changes in neurologic function and in the extent of lesions on MRI. The primary end point was being alive and having no major functional disability at 24 months after infusion. RESULTS: A total of 17 boys received Lenti-D gene therapy. At the time of the interim analysis, the median follow-up was 29.4 months (range, 21.6 to 42.0). All the patients had gene-marked cells after engraftment, with no evidence of preferential integration near known oncogenes or clonal outgrowth. Measurable ALD protein was observed in all the patients. No treatment-related death or graft-versus-host disease had been reported; 15 of the 17 patients (88%) were alive and free of major functional disability, with minimal clinical symptoms. One patient, who had had rapid neurologic deterioration, had died from disease progression. Another patient, who had had evidence of disease progression on MRI, had withdrawn from the study to undergo allogeneic stem-cell transplantation and later died from transplantation-related complications. CONCLUSIONS: Early results of this study suggest that Lenti-D gene therapy may be a safe and effective alternative to allogeneic stem-cell transplantation in boys with early-stage cerebral adrenoleukodystrophy. Additional follow-up is needed to fully assess the duration of response and long-term safety. (Funded by Bluebird Bio and others; STARBEAM ClinicalTrials.gov number, NCT01896102 ; ClinicalTrialsRegister.eu number, 2011-001953-10 .).
引用
- Eichler F, Duncan C, Musolino PL, et al. Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy. N Engl J Med. 2017. PMID: 28976817. doi:10.1056/NEJMoa1700554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。